Skip to Content

Olanzapine Cipla

Previous name: Olanzapine Neopharma
Active Substance: olanzapine
Common Name: olanzapine
ATC Code: N05AH03
Marketing Authorisation Holder: Cipla (EU) Limited
Active Substance: olanzapine
Status: Withdrawn
Authorisation Date: 2007-11-14
Therapeutic Area: Bipolar Disorder Schizophrenia
Pharmacotherapeutic Group: Psycholeptics

Therapeutic Indication

Adults

Olanzapine is indicated for the treatment of schizophrenia.

Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.

Olanzapine is indicated for the treatment of moderate to severe manic episode.

In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.

The marketing authorisation for Olanzapine Cipla has been withdrawn at the request of the marketing-authorisation holder.

Source: European Medicines Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide